London's Boltz raises $110M Series A led by Bessemer to scale its AI models for drug discovery
What's the deal? Boltz, the London-based AI lab behind the open-source Boltz models for biomolecular structure prediction and design, has raised a $110 million Series A led by Bessemer Venture Partners. Existing backers Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures all invested again, joined by new investors Greycroft, F-Prime Capital, Hummingbird and Benchling. Bessemer's Andrew Hedin and Byron Deeter join the company.
Traction: Boltz says it has signed partnerships with six of the world's 20 largest pharma companies, including Pfizer, GSK, Takeda and BMS, and that molecular token usage among paying customers has grown 50-fold since June, when it released its first proprietary models, BoltzMol-1 for small molecules and BoltzProt-1 for proteins. It sells access through an API billed on token usage. Bessemer says the open-source models have passed 5 million downloads and are used by more than 100,000 scientists.
Context: The founders, CEO Gabriele Corso, CTO Jeremy Wohlwend and head of research Saro Passaro, were core developers of the Boltz models in Regina Barzilay's lab at MIT CSAIL and the Jameel Clinic. The company raised a $28 million seed round led by Andreessen Horowitz, Amplify and Zetta, and has grown to about 40 scientists and engineers. The new money goes to compute, data and hiring.
Sources: Boltz
Bessemer Venture Partners
Greycroft
SiliconANGLE
Image credit: Bessemer Venture Partners